Drug Profile
Research programme: Duchenne muscular dystrophy therapeutics - Atlantic Gene Therapies/Genethon/Institute of Myology
Latest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator Genethon
- Developer Atlantic Gene Therapies; Genethon; Institut de Myologie
- Class Gene therapies
- Mechanism of Action Dystrophin expression stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Duchenne muscular dystrophy
Most Recent Events
- 24 Jul 2023 Discontinued - Preclinical for Duchenne muscular dystrophy in France (IM)
- 28 Dec 2018 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in France (IM, Injection)
- 10 Nov 2014 Preclinical trials in Duchenne muscular dystrophy in France (IM)